Amifostine
Ethyol (amifostine) is a small molecule pharmaceutical. Amifostine was first approved as Ethyol on 1995-12-08. It is used to treat experimental radiation injuries in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amifostine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ETHYOL | Cosette Pharmaceuticals | N-020221 DISCN | 1995-12-08 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ethyol | New Drug Application | 2023-11-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| experimental radiation injuries | — | D011833 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0207 | Injection, amifostine, 500 mg |
Clinical
Clinical Trials
86 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 7 | 13 | 1 | 1 | — | 19 |
| Head and neck neoplasms | D006258 | — | — | 4 | 13 | 1 | 1 | 1 | 16 |
| Neoplasms | D009369 | — | C80 | 8 | 5 | 1 | 1 | 1 | 15 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 10 | 1 | 1 | 1 | 14 |
| Lymphoma | D008223 | — | C85.9 | 3 | 4 | — | 1 | — | 7 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiation injuries | D011832 | — | T66 | 4 | 9 | 1 | — | — | 11 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 8 | 1 | — | — | 10 |
| Radiation effects | D011830 | — | — | 3 | 9 | 1 | — | — | 10 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 6 | 1 | — | — | 7 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 4 | 1 | — | — | 5 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | — | 1 | — | — | 4 |
| Neurotoxicity syndromes | D020258 | — | G92 | — | 3 | 1 | — | — | 4 |
| Xerostomia | D014987 | — | K11.7 | — | 2 | 1 | — | — | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | 1 | — | — | 2 |
| Hydatidiform mole | D006828 | — | O01 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 8 | — | — | — | 9 |
| Leukemia | D007938 | — | C95 | 6 | 6 | — | — | — | 9 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 7 | — | — | — | 7 |
| Sarcoma | D012509 | — | — | 3 | 4 | — | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 5 | — | — | — | 6 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 3 | — | — | — | 5 |
| Refractory anemia with excess of blasts | D000754 | — | D46.2 | 1 | 5 | — | — | — | 5 |
| Refractory anemia | D000753 | — | D46.4 | — | 4 | — | — | — | 4 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 1 | 2 | — | — | — | 3 |
Show 55 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | — | — | 3 | — | — | — | — | 3 |
| Plasmacytoma | D010954 | — | C90.3 | 2 | — | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 1 | — | — | — | — | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | — | — | — | — | 1 |
| Retinoblastoma | D012175 | — | — | 1 | — | — | — | — | 1 |
| Chordoma | D002817 | EFO_0000334 | — | 1 | — | — | — | — | 1 |
| Prolymphocytic leukemia | D015463 | — | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amifostine |
| INN | amifostine |
| Description | Amifostine is an organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy. It has a role as a prodrug, a radiation protective agent and an antioxidant. It is a diamine and an organic thiophosphate. It is functionally related to a cysteamine. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCCNCCSP(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 20537-88-6 |
| RxCUI | 1545987 |
| ChEMBL ID | CHEMBL1006 |
| ChEBI ID | 2636 |
| PubChem CID | 2141 |
| DrugBank | DB01143 |
| UNII ID | ILA426L95O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ethyol – Cumberland Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,863 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
848 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use